Abstract
Schizophrenia is characterised by positive, negative, cognitive, depressive and anxiety symptoms. Over the last decades a number of novel treatment strategies with better clinical efficacy and scope, but with lower side-effect profiles have been developed. These have significantly improved the management and prognosis of the disease. Of these approaches, modulation of the serotonergic receptor system is a common, recurring, theme; particularly the use of 5-HT1A receptor agonism as part of or adjunct to existing therapies. Here we review data exploring the utility of 5-HT1A receptor agonists for extending the actions of antipsychotic agents, while limiting their side-effect profile. Notably, interest has grown concerning 5-HT1A receptor activation in schizophrenia because of the development of novel antipsychotics, such as lurasidone and cariprazine, the characterisation of 5-HT1A receptor polymorphisms in schizophrenia patients and the possible beneficial influence of 5-HT1A agonists on neurogenesis.
Keywords: Schizophrenia, 5-HT1A, negative symptoms, cognitive symptoms, psychosis, clinical, non-clinical.
Current Pharmaceutical Design
Title:Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs
Volume: 21 Issue: 26
Author(s): Andrew C. McCreary and Adrian Newman-Tancredi
Affiliation:
Keywords: Schizophrenia, 5-HT1A, negative symptoms, cognitive symptoms, psychosis, clinical, non-clinical.
Abstract: Schizophrenia is characterised by positive, negative, cognitive, depressive and anxiety symptoms. Over the last decades a number of novel treatment strategies with better clinical efficacy and scope, but with lower side-effect profiles have been developed. These have significantly improved the management and prognosis of the disease. Of these approaches, modulation of the serotonergic receptor system is a common, recurring, theme; particularly the use of 5-HT1A receptor agonism as part of or adjunct to existing therapies. Here we review data exploring the utility of 5-HT1A receptor agonists for extending the actions of antipsychotic agents, while limiting their side-effect profile. Notably, interest has grown concerning 5-HT1A receptor activation in schizophrenia because of the development of novel antipsychotics, such as lurasidone and cariprazine, the characterisation of 5-HT1A receptor polymorphisms in schizophrenia patients and the possible beneficial influence of 5-HT1A agonists on neurogenesis.
Export Options
About this article
Cite this article as:
McCreary C. Andrew and Newman-Tancredi Adrian, Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs, Current Pharmaceutical Design 2015; 21 (26) . https://dx.doi.org/10.2174/1381612821666150605105215
DOI https://dx.doi.org/10.2174/1381612821666150605105215 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mathematical Models of Behavior of Individual Animals
Current Pharmaceutical Design Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients
Current Drug Safety New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Pharmacogenetic and Pharmacogenomic Research in Psychiatry: Current Advances and Clinical Applications
Current Pharmacogenomics Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications
Current Neuropharmacology Novel Treatments of Schizophrenia: Targeting the Neurotensin System
CNS & Neurological Disorders - Drug Targets Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Current Neuropharmacology Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology Neurodegenerative Disorders and the Current State, Pathophysiology, and Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Antipsychotic Polypharmacy
Current Pharmaceutical Design Recent Advances on Nitric Oxide in the Upper Airways
Current Medicinal Chemistry Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Data Visualization and Feature Selection Methods in Gel-based Proteomics
Current Protein & Peptide Science Antipsychotic Medication: The Potential Role of 5-HT1A Receptor Agonism
Current Pharmaceutical Design Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson’s Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Evaluation of B Lymphocyte Deficiencies
Cardiovascular & Hematological Disorders-Drug Targets Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Mobile Phone Text Message Interventions in Psychiatry - What are the Possibilities?
Current Psychiatry Reviews The Development of High-throughput Identification and Heterologous Expression of Valuable Peptides/Proteins
Current Proteomics Dopamine Receptor Pharmacology: Interactions with Serotonin Receptors and Significance for the Aetiology and Treatment of Schizophrenia
CNS & Neurological Disorders - Drug Targets